LUYE PHARMA (02186) rose nearly 5% in Hong Kong trading. At the time of writing, the stock was up 3.69% to HK$2.81, with a trading volume of HK$105 million. The catalyst for the movement was the company's 2025 earnings report, released on March 31. The report showed revenue increased by 4.1% year-on-year to RMB 6.308 billion. Profit attributable to shareholders reached approximately RMB 619 million, representing a significant year-on-year growth of 31.12%. Basic earnings per share were 15.88 fen. According to the announcement, the revenue growth was driven by increased sales and licensing income from certain products.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments